Objective
A highly effective malaria vaccine against Plasmodium falciparum should help prevent half a million deaths from malaria each year. New vaccine technologies and antigen discovery approaches now make accelerated design and development of a highly effective multi-antigen multi-stage subunit vaccine feasible. Leading malariologists, vaccine researchers and product developers will here collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates.
Our approach tackles the toughest problems in malaria vaccine design: choice of the best antigens, attaining high immunogenicity, avoiding polymorphic antigens and increasing the durability of vaccine immunogenicity and efficacy.
We take advantage of several recent advances in vaccinology and adopt some very new technologies: sequencing malaria peptides eluted from the HLA molecules, parasites expressing multiple transgenes, multi-antigen virus-like particles constructed with new bonding technologies, delayed release microcapsules, and liver-targeted immunisation with vaccine vectors.
We enhance our chances of success by using a multi-stage multi-antigen approach, by optimising the magnitude and durability of well-characterised immune responses to key antigens, and using stringent infectious challenges and functional assays as established criteria for progression at each stage.
The consortium comprises many of the foremost researchers in this field in Europe with leading groups in the USA, Australia and Africa. We link to EDCTP programmes and harmonise our timeline to fit with the recent roadmaps for malaria vaccine development. We include a major pharma partner and several excellent European biotech companies helping enhance Europe’s leading position in the commercial development of vaccines.
This ambitious and exciting programme should have a high chance of success in tackling the major global health problem posed by malaria.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
OX1 2JD Oxford
United Kingdom
See on map
Participants (18)
Participation ended
6525 XZ Nijmegen
2333 ZA Leiden
See on map
75006 Paris
See on map
Participation ended
NW1 2BE London
13572 Marseille
See on map
2300 Kobenhavn S
See on map
1015 Lausanne
See on map
753 18 Uppsala
See on map
2970 Horsholm
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
75001 Paris
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4811 Townsville
See on map
98107-5136 Seattle Wa
See on map
Participation ended
SN2 1FL Swindon
2333 CN Leiden
See on map
75008 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6525 GA Nijmegen
See on map
1228 Plan Les Ouates
See on map
WC1E 7HT London
See on map